Research Report
Databases, Protein
Internet
User-Computer Interface
Software
Venous Pressure
Polyethylene Terephthalates
Polyesters
Second-Look Surgery
Phthalic Acids
Textile Industry
Acetogenins
Annonaceae
Annona
Benzethonium
Bactericidal cationic quaternary ammonium surfactant used as a topical anti-infective agent. It is an ingredient in medicaments, deodorants, mouthwashes, etc., and is used to disinfect apparatus, etc., in the food processing and pharmaceutical industries, in surgery, and also as a preservative. The compound is toxic orally as a result of neuromuscular blockade.
Furans
Mustelidae
Portraits as Topic
Saint Lucia
An independent state in the West Indies. Its capital is Castries. It was probably discovered by Columbus in 1502 and first settled by the English in 1605. Contended for by the French and English in the 17th century, it was regarded as neutral in 1748 but changed hands many times in the wars of the 19th century. It became a self-governing state in association with Great Britain in 1967 and achieved independence in 1979. Columbus named it for the day on which he discovered it, the feast of St. Lucy, a Sicilian virgin martyr. (From Webster's New Geographical Dictionary, 1988, p1051 & Room, Brewer's Dictionary of Names, 1992, p477)
Teratology
Desulfovibrio
Butylated Hydroxyanisole
Pantothenic Acid
Silicone Elastomers
Polymers of silicone that are formed by crosslinking and treatment with amorphous silica to increase strength. They have properties similar to vulcanized natural rubber, in that they stretch under tension, retract rapidly, and fully recover to their original dimensions upon release. They are used in the encapsulation of surgical membranes and implants.
Hair
Elastomers
Hair Follicle
A tube-like invagination of the EPIDERMIS from which the hair shaft develops and into which SEBACEOUS GLANDS open. The hair follicle is lined by a cellular inner and outer root sheath of epidermal origin and is invested with a fibrous sheath derived from the dermis. (Stedman, 26th ed) Follicles of very long hairs extend into the subcutaneous layer of tissue under the SKIN.
Bibliometrics
Publications
Petasites
Research
Critical and exhaustive investigation or experimentation, having for its aim the discovery of new facts and their correct interpretation, the revision of accepted conclusions, theories, or laws in the light of newly discovered facts, or the practical application of such new or revised conclusions, theories, or laws. (Webster, 3d ed)
Publishing
Fenclonine
Fear
Amphetamines
Ketanserin
Receptor, Serotonin, 5-HT2A
A serotonin receptor subtype found widely distributed in peripheral tissues where it mediates the contractile responses of variety of tissues that contain SMOOTH MUSCLE. Selective 5-HT2A receptor antagonists include KETANSERIN. The 5-HT2A subtype is also located in BASAL GANGLIA and CEREBRAL CORTEX of the BRAIN where it mediates the effects of HALLUCINOGENS such as LSD.
Serotonin Antagonists
Receptor, Serotonin, 5-HT2C
A serotonin receptor subtype found primarily in the CENTRAL NERVOUS SYSTEM and the CHOROID PLEXUS. This receptor subtype is believed to mediate the anorectic action of SEROTONIN, while selective antagonists of the 5-HT2C receptor appear to induce ANXIETY. Several isoforms of this receptor subtype exist, due to adenine deaminase editing of the receptor mRNA.
Mibefradil (Ro 40-5967) inhibits several Ca2+ and K+ currents in human fusion-competent myoblasts. (1/606)
1. The effect of mibefradil (Ro 40-5967), an inhibitor of T-type Ca2+ current (I(Ca)(T)), on myoblast fusion and on several voltage-gated currents expressed by fusion-competent myoblasts was examined. 2. At a concentration of 5 microM, mibefradil decreases myoblast fusion by 57%. At this concentration, the peak amplitudes of I(Ca)(T) and L-type Ca2+ current (I(Ca)(L)) measured in fusion-competent myoblasts are reduced by 95 and 80%, respectively. The IC50 of mibefradil for I(Ca)(T) and I(Ca)(L) are 0.7 and 2 microM, respectively. 3. At low concentrations, mibefradil increased the amplitude of I(Ca)(L) with respect to control. 4. Mibefradil blocked three voltage-gated K+ currents expressed by human fusion-competent myoblasts: a delayed rectifier K+ current, an ether-a-go-go K+ current, and an inward rectifier K+ current, with a respective IC50 of 0.3, 0.7 and 5.6 microM. 5. It is concluded that mibefradil can interfere with myoblast fusion, a mechanism fundamental to muscle growth and repair, and that the interpretation of the effect of mibefradil in a given system should take into account the action of this drug on ionic currents other than Ca2+ currents. (+info)Developmental regulation of expression of the D3 dopamine receptor in rat nucleus accumbens and islands of Calleja. (2/606)
The dopamine D3 receptor (D3R) belongs to the D2 subfamily and is expressed in the rat brain in targets of the mesolimbic dopaminergic system. Little is known about its normal development and control by dopaminergic innervation. We studied developmental expression of D3R in the rat nucleus accumbens (NAC) and islands of Calleja (ISC). At postnatal day (P) 7, D3 binding sites and mRNA were low in both areas. By P14, D3R and mRNA concentrations were close to adult levels in the ISC, whereas, in the NAC, binding increased until 3 months after birth. Cellular concentrations of D3 mRNA in the ISC increased with age in conjunction with a decrease in the number of D3 positive cells. In the NAC, the number of positive cells increased, whereas cellular levels of expression remained unchanged. Neonatal 6-hydroxydopamine lesion caused age-dependent changes in D3R expression. D3 binding sites did not change at P7 or P14, but there was a reduction in the number of D3 mRNA positive neurons accompanied by an increase in cellular levels of D3 mRNA at P14, suggesting that changes occurred in a subset of neurons. Up-regulation of D3 binding sites in NAC and ISC occurred 1 month after the lesion (P35) concomitant with a decrease in cellular levels of D3 mRNA and the number of D3 mRNA positive cells. At 3 months (P90) after the lesion, an increase in D3 mRNA occurred with no change in D3 binding sites. D3R shows region-specific dynamics in receptor/mRNA expression during development and is sensitive to loss of dopamine in early postnatal development. (+info)Genetic analysis of biodegradation of tetralin by a Sphingomonas strain. (3/606)
A strain designated TFA which very efficiently utilizes tetralin has been isolated from the Rhine river. The strain has been identified as Sphingomonas macrogoltabidus, based on 16S rDNA sequence similarity. Genetic analysis of tetralin biodegradation has been performed by insertion mutagenesis and by physical analysis and analysis of complementation between the mutants. The genes involved in tetralin utilization are clustered in a region of 9 kb, comprising at least five genes grouped in two divergently transcribed operons. (+info)Central hypothyroidism associated with retinoid X receptor-selective ligands. (4/606)
BACKGROUND: The occurrence of symptomatic central hypothyroidism (characterized by low serum thyrotropin and thyroxine concentrations) in a patient with cutaneous T-cell lymphoma during therapy with the retinoid X receptor-selective ligand bexarotene led us to hypothesize that such ligands could reversibly suppress thyrotropin production by a thyroid hormone-independent mechanism and thus cause central hypothyroidism. METHODS: We evaluated thyroid function in 27 patients with cutaneous T-cell lymphoma who were enrolled in trials of high-dose oral bexarotene at one institution. In addition, we evaluated the in vitro effect of triiodothyronine, 9-cis-retinoic acid, and the retinoid X receptor-selective ligand LGD346 on the activity of the thyrotropin beta-subunit gene promoter. RESULTS: The mean serum thyrotropin concentration declined from 2.2 mU per liter at base line to 0.05 mU per liter during treatment with bexarotene (P<0.001), and the mean serum free thyroxine concentration declined from 1.0 ng per deciliter (12.9 pmol per liter) at base line to 0.45 ng per deciliter (5.8 pmol per liter) (P<0.001) during treatment. The degree of suppression of thyrotropin secretion tended to be greater in patients treated with higher doses of bexarotene (>300 mg per square meter of body-surface area per day) and in those with a history of treatment with interferon alfa. Nineteen patients had symptoms or signs of hypothyroidism, particularly fatigue and cold intolerance. The symptoms improved after the initiation of thyroxine therapy, and all patients became euthyroid after treatment with bexarotene was stopped. In vitro, LGD346 suppressed the activity of the thyrotropin beta-subunit gene promoter in thyrotrophs by as much as 50 percent, an effect similar to that of triiodothyronine and 9-cis-retinoic acid. CONCLUSIONS: Hypothyroidism may develop in patients with cutaneous T-cell lymphoma who are treated with high-dose bexarotene, most likely because the retinoid X receptor-selective ligand suppresses thyrotropin secretion. (+info)Estradiol modulates vascular response to melatonin in rat caudal artery. (5/606)
The purpose of this study was to determine whether estrogen modulates the function of vascular melatonin receptors. We used the rat caudal artery and found that the contractile effects of melatonin were influenced by the estrous cycle, ovariectomy, and estrogen replacement. In arterial ring segments isolated from female rats, melatonin potentiated, in a concentration-dependent manner, contractions produced either by adrenergic nerve stimulation or by phenylephrine. Constrictor responses to melatonin were smaller in arteries from female rats in proestrus compared with other stages of the estrous cycle and after ovariectomy. Administration of 17beta-estradiol to ovariectomized female rats also resulted in decreased constriction of isolated arteries to melatonin; however, in vitro addition of 17beta-estradiol (10(-7) M) had no effect. In the caudal artery, melatonin appears to act on two receptor subtypes that mediate contraction and relaxation, respectively. The selective melatonin MT2-receptor antagonist 4-phenyl-2-propionamidotetraline (4P-PDOT) enhanced constrictor responses to melatonin in arterial segments from intact female rats, consistent with the inhibition of MT2 receptor-mediated relaxation. In contrast, 4P-PDOT had no significant effect in arteries from ovariectomized female rats. However, when estradiol was replaced in vivo, the effect of 4P-PDOT on melatonin responses was restored. Thus circulating estradiol appears to enhance MT2 melatonin-receptor function in the thermoregulatory caudal artery of the female rat resulting in increased vasodilatation in response to melatonin. (+info)Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations. (6/606)
AIMS: To determine the effects of mibefradil on the nletabolism in human liver microsomal preparations of the HMG-CoA reductase inhibitors simvastatin, lovastatin, atorvastatin, cerivastatin and fluvastatin. METHODS: Metabolism of the above five statins (0.5, 5 or 10 microM), as well as of specific CYP3A4/5 and CYP2C8/9 marker substrates, was examined in human liver microsomal preparations in the presence and absence of mibefradil (0.1-50 microM). RESULTS: Mibefradil inhibited, in a concentration-dependent fashion, the metabolism of the four statins (simvastatin, lovastatin, atorvastatin and cerivastatin) known to be substrates for CYP3A. The potency of inhibition was such that the IC50 values (<1 microM) for inhibition of all of the CYP3A substrates fell within the therapeutic plasma concentrations of mibefradil, and was comparable with that of ketoconazole. However, the inhibition by mibefradil, unlike that of ketoconazole, was at least in part mechanism-based. Based on the kinetics of its inhibition of hepatic testosterone 6beta-hydroxylase activity, mibefradil was judged to be a powerful mechanism-based inhibitor of CYP3A4/5, with values for Kinactivation, Ki and partition ratio (moles of mibefradil metabolized per moles of enzyme inactivated) of 0.4 min(-1), 2.3 microM and 1.7, respectively. In contrast to the results with substrates of CYP3A, metabolism of fluvastatin, a substrate of CYP2C8/9, and the hydroxylation of tolbutamide, a functional probe for CYP2C8/9, were not inhibited by mibefradil. CONCLUSION: Mibefradil, at therapeutically relevant concentrations, strongly suppressed the metabolism in human liver microsomes of simvastatin, lovastatin, atorvastatin and cerivastatin through its inhibitory effects on CYP3A4/5, while the effects of mibefradil on fluvastatin, a substrate for CYP2C8/9, were minimal in this system. Since mibefradil is a potent mechanism-based inhibitor of CYP3A4/5, it is anticipated that clinically significant drug-drug interactions will likely ensue when mibefradil is coadministered with agents which are cleared primarily by CYP3A-mediated pathways. (+info)Morphological transformation induced by activation of the mitogen-activated protein kinase pathway requires suppression of the T-type Ca2+ channel. (7/606)
Transformation of fibroblasts by various oncogenes, including ras, mos, and src accompanies with characteristic morphological changes from flat to round (or spindle) shapes. Such morphological change is believed to play an important role in establishing malignant characteristics of cancer cells. Activation of the mitogen-activated protein kinase (MAPK) pathway is a converging downstream event of transforming activities of many oncogene products commonly found in human cancers. Intracellular calcium is known to regulate cellular morphology. In fibroblasts, Ca2+ influx is primarily controlled by two types of Ca2+ channels (T- and L-types). Here, we report that the T-type current was specifically inhibited in cells expressing oncogenically activated Ras as well as gain-of-function mutant MEK (MAPK/extracellular signal-regulated kinase (ERK) kinase, a direct activator of MAPK), whereas treatment of ras-transformed cells with a MEK-specific inhibitor restored T-type Ca2+ channel activity. Using a T-type Ca2+ channel antagonist, we further found that suppression of the T-type Ca2+ channel by the activated MAPK pathway is a prerequisite event for the induction and/or maintenance of transformation-associated morphological changes. (+info)Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Netherlands Working Group on Cardiovascular Research (WCN). (8/606)
AIMS: The combination of calcium channel blockers and beta-adrenoceptor blockers is more effective for the treatment of exercise-induced angina pectoris than beta-adrenoceptor blocker monotherapy. As ischaemia in exercise-induced angina is preceded by increase in heart rate, calcium channel blockers with negative chronotropic properties may perform better for this purpose than nonchronotropic compounds. METHODS: A 335 patient double-blind parallel-group study comparing 14 day treatment with amlodipine 5 and 10 mg, with diltiazem 200 and 300 mg, and mibefradil 50 and 100 mg added to baseline beta-adrenoceptor blocker treatment was performed. Exercise testing (ETT) was performed by bicycle ergometry. RESULTS: Although none of the calcium channel blockers improved duration of exercise or amount of workload, all significantly delayed onset of 1 mm ST-segment depression on ETT (P<0.001 for any treatment vs baseline). In addition, mibefradil, both low and high dose treatment, produced the longest delays (low dose: different from diltiazem and amlodipine by 24.1 and 29.8 s, respectively, P<0. 003 and <0.001; high dose: different from diltiazem and amlodipine by 33.7 and 37.0 s, respectively, P<0.001 and <0.001). These effects were linearly correlated with the reduction in rate pressure product (RPP). Serious symptoms of dizziness occurred significantly more frequently on mibefradil (P<0.05), and 19 patients on mibefradil withdrew from trial. CONCLUSIONS: Calcium channel blockers with negative chronotropic properties provide greater delay of ischaemia in patients with exercise-induced angina, but the concomitant risk of intolerable dizziness attenuates this benefit. (+info)
Global Market Report of 1,1,4,4,6-Pentamethyl-1,2,3,4-tetrahydronaphthalene (CAS 6683-48-3)
DGIST Scholar: Effect of bexarotene on differentiation of glioblastoma multiforme compared with ATRA
The effects of the dopamine agonist rotigotine on hemispatial neglect following stroke. - Wellcome Centre for Integrative...
RXR-Selective retinoid, Bexarotene (Targretin) upregulates IL2R expression and enhances sensitivity of B-chronic lymphocytic...
Bexarotene Reduces Blood-Brain Barrier Permeability in Cerebral Ischemia-Reperfusion Injured Rats
The RXR Agonist Bexarotene Improves Cholesterol Homeostasis and Inhibits Atherosclerosis Progression in a Mouse Model of Mixed...
1-phenyl-3-dimethylamino-6-chloro-7-hydroxy-1,2,3,4-tetrahydronaphthalene
Summary Report | CureHunter
Medications Cheap Drugs - Bexarotene online
2-CHLORO-1-(5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)ETHANONE (CAS 5803-67-8) Market Research Report 2018
A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia | Clinical Cancer Research
Dual efficacy of delta opioid receptor-selective ligands for ethanol drinking and anxiety<...
CAS 170638-05-8 (R)-7-Methoxy-2-aminotetraline hydrochloride - BOC Sciences
2S)-7-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine hydrochloride, in stock
6-Chloro-1,2,3,4-tetrahydronaphthalen-2-amine | C10H12ClN - PubChem
Bexarotene QuickView - Correlation Engine
Patent US5856490 - Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and ... - Google Patents
Targretin® (bexarotene) gel
1% - Drug label and information - Rx Drugs Info
5,6-dimethoxy-2-aminotetraline hydrochloride | Building block | CAS [21489-75-8] - [21489-50-9] | Axon 1042 | Axon Ligand™ with...
Targretin (Bexarotene): Side Effects, Interactions, Warning, Dosage & Uses
Bexarotenes Effects Vary by ApoE Genotype, Amyloid Pathology | ALZFORUM
Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia - Full Text View -...
1S)-1,2,3,4-tetrahydronaphthalen-1-amine - Registration Dossier - ECHA
1S)-1,2,3,4-tetrahydronaphthalen-1-amine - Registration Dossier - ECHA
Once-Weekly Subcutaneous Delivery of Polymer-Linked Rotigotine (SER-214) Provides Continuous Plasma Levels in Parkinsons...
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease...
S. Chandran
The Rexinoids LG100268 and LG101506 Inhibit Inflammation and Suppress Lung Carcinogenesis in A/J Mice | Cancer Prevention...
Naphthalene,1,2,3,4-tetrahydro-1,1,6-trimethyl-;475-03-6
AAN: Rotigotine Eases Non-Motor Parkinsons Symptoms | Medpage Today
Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV...
Bexarotene capsules
PB28 - Википедија, слободна енциклопедија
Is Rotigotine Neupro safe when allergic to sulfates and suffering from AFIB?
CiNii Articles - Matsuura Tomomi
ebelactone A | Semantic Scholar
Enhanced Efficacy of Combinations of Retinoic Acid- and Retinoid X Receptor-selective Retinoids and α-Interferon in Inhibition...
Receptor specificity of retinoid-induced epidermal hyperplasia: effect of RXR-selective agonists and correlation with topical...
Plus it
Ligand Expands License with Sermonix to Include Worldwide Rights for Oral Lasofoxifene :: Ligand Pharmaceuticals Incorporated ...
PatientsLikeMe | Bexarotene report for patients like you
Pesquisa | Portal Regional da BVS
Could Bexarotene Treat Parkinsons Disease? | ALZFORUM
Investigators Present Targretin Lung Cancer Data From SPIRIT I & II Trials
Growth factor-antagonized rexinoid apoptosis involves permissive PPARgamma/RXR heterodimers to activate the intrinsic death...
A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia
Patients Who Have Received Prior Therapy with ATRA and...
Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical...
BLOG - Page 39 of 39 - BrainStromBrainStrom | Power of Science | Page 39
Where can i buy the homeopathic for bexarotene - Venapro Herbal Hemorrhoids Treatment - Jan 22, 2018
Bexarotene Capsules 75 Mg | Canadian Pharcharmy Online
JCI -
Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A
Alzheimers Disease New Treatments |IYTHEALTH.com
The |i|Neupro|/i| (NU-pro, rotigotine) patch will be back for Parkinsons disease, and its now also approved for restless legs...
Doktor Liliy Koval
Pfizer Receives FDA Complete Response Letter for Lasofoxifene
WikiGenes - Targret - 4-[1-(3,5,5,8,8-pentamethyl-6,7...
Retinoid and Rexinoid Signaling - Methods and Protocols | Swapan Ray | Springer
2016 Grant Recipient David Linehan, MD - Pancreatic Cancer Action Network
Buy Headlight Set-Base Anzo 881035 online | eBay
Selective glucocorticoid receptor modulator
... tetrahydronaphthalenes with alternative steroidal A-ring mimetics possessing dissociated (transrepression/transactivation) ...
Amitriptyline
4-tetrahydronaphthalenes". Bioorg. Med. Chem. 14 (19): 6640-58. doi:10.1016/j.bmc.2006.05.077. PMID 16782354. Nguyen T, Shapiro ...
Diphenhydramine
4-tetrahydronaphthalenes". Bioorganic & Medicinal Chemistry. 14 (19): 6640-58. doi:10.1016/j.bmc.2006.05.077. PMID 16782354. ...
Mianserin
4-tetrahydronaphthalenes". Bioorg. Med. Chem. 14 (19): 6640-58. doi:10.1016/j.bmc.2006.05.077. PMID 16782354. Appl H, Holzammer ...
Nortriptyline
4-tetrahydronaphthalenes". Bioorg. Med. Chem. 14 (19): 6640-58. doi:10.1016/j.bmc.2006.05.077. PMID 16782354. Stanton T, Bolden ...
List of selective estrogen receptor modulators
... tetrahydronaphthalenes (lasofoxifene, nafoxidine), and benzopyrans (acolbifene, ormeloxifene, levormeloxifene). Pinkerton, ...
Stereoselectivity
4-tetrahydronaphthalenes Friedrich Mühlthau, Thorsten Bach Synthesis 2005: 3428-3436 doi:10.1055/s-2005-918482 High Facial ...
List of MeSH codes (D04)
... tetrahydronaphthalenes MeSH D04.615.638.960.400 - 8-hydroxy-2-(di-n-propylamino)tetralin MeSH D04.615.638.960.492 - levobunolol ...
Tetrahydronaphthalenes Diagnostic Use | Keywords | Survey Research Center
OBJECTIVE: To explore the neurochemical basis of REM sleep behavior disorder (RBD) in multiple-system atrophy (MSA). METHODS: In 13 patients with probable MSA, nocturnal, laboratory-based polysomnography was used to rate the severity of REM atonia loss by the percentage of REM sleep with tonically increased electromyographic (EMG) activity and the percentage of REM sleep with phasic EMG bursts. PET with (+)-[11C]dihydrotetrabenazine ([11C]DTBZ) was employed to measure the density of striatal monoaminergic terminals and SPECT with (-)-5-[123I]iodobenzovesamicol ([123I]IBVM) to measure the density of 123I]IBVM. RESULTS: Age and gender distributions were similar in patient and normal control groups. The MSA subjects showed decreased mean [11C]DTBZ binding in the striatum (p , 0.0001) and decreased [123I]IBVM binding in the thalamus (p , 0.001). Moreover, in the MSA group, striatal [11C]DTBZ binding was inversely correlated with the severity of REM atonia loss (p = 0.003). Thalamic [123I]IBVM ...
RCSB PDB - EVP Ligand Summary Page
The PDB archive contains information about experimentally-determined structures of proteins, nucleic acids, and complex assemblies. As a member of the wwPDB, the RCSB PDB curates and annotates PDB data according to agreed upon standards. The RCSB PDB also provides a variety of tools and resources. Users can perform simple and advanced searches based on annotations relating to sequence, structure and function. These molecules are visualized, downloaded, and analyzed by users who range from students to specialized scientists.
Molecules | Free Full-Text | Synthesis and Anticancer Activity of Some Novel Tetralin-6-yl-pyrazoline, 2-Thioxopyrimidine, 2...
The rexinoid LG100754 is a novel RXR:PPARgamma agonist and decreases glucose levels in vivo
Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers
MEDLINE - Resultado p gina 1
Yr Athro Thomas Wirth - Pobl - Prifysgol Caerdydd
TNO Repository search for: subject:'Retinoic acid'
Patent US3385831 - Textile fibers of polyethylene terephthalate/hexahydroterephthalate copolyester - Google Patents
Search Results
Selective glucocorticoid receptor modulator - Wikipedia
BJOC - Multicomponent reactions II
EP0874800B1 - Indane dimer compounds with smooth muscle relaxing and/or mast cell stabilising and/or antiinflammatory activity ...
Browsing Pharmacognosy (Theses and Dissertations) by Title
Nicholas Oberlies , NC DOCKS (North Carolina Digital Online Collection of Knowledge and Scholarship)
Amitriptyline - Wikipedia
MPI-INF D3 Publications, generated: 1:16, 17 December 2017
MPI-INF D3 Publications - 1. Author,Editor - 2. by Group - 1. by Names of First Author,Editor, MPI-INF D3 Publications -...
US20090306026A1 - Pharmaceutical Formulations and Uses Thereof in the Treatment of Female Sexual Dysfunction
- Google...
WikiGenes - TH - tyrosine hydroxylase
relapsed mycosis fungoides drug therapy 2000:2010[pubdate] *count=100 - BioMedLib™ search engine
mycosis fungoides stage ii drug therapy 2000:2010[pubdate] *count=100 - BioMedLib™ search engine
Tetrahydronaphthalenes / therapeutic use. *[MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cohort Studies. Female. ... Tetrahydronaphthalenes / administration & dosage. *[MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gels. Humans. Male. ... Tetrahydronaphthalenes / therapeutic use. *[MeSH-minor] Algorithms. Dermatitis, Exfoliative / complications. Dermatitis, ... Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Gels; 0 / Tetrahydronaphthalenes; A61RXM4375 / bexarotene ...
Patent WO2005110353A1 - Personal care compositions and methods for regulating mammalian hair growth ... - Google Patentsuche
Scott E Denmark - Research Output
- University of Illinois at Urbana-Champaign
Arylmagnesium Bromide Additions to 1-Tetralone-2-acetic Acid Followed by Catalytic Hydrogenolysis: Stereochemical Consequences ...
promethazine | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
The Curious Wavefunction: A simple substitution to possibly avoid phenol elimination
The Curious Wavefunction: 2007
Characterization of the dopamine-responsive adenylate cyclase of bovine parathyroid cells and its relationship to parathyroid...
TY - JOUR. T1 - Characterization of the dopamine-responsive adenylate cyclase of bovine parathyroid cells and its relationship to parathyroid hormone secretion. AU - Attie, M. F.. AU - Brown, E. M.. AU - Gardner, D. G.. AU - Spiegel, A. M.. AU - Aurbach, G. D.. PY - 1980/12. Y1 - 1980/12. N2 - To investigate further the mechanism of dopamine (DA)-stimulated parathyroid hormone (PTH) secretion, we have identified and studied DA-sensitive adenylate cyclase in a particulate preparation of osmotically lysed dispersed bovine parathyroid cells. Adenylate cyclase was responsive to DA at concentrations as low as 0.3 μM, and the maximal stimulation in the presence of GTP was 2- to 4-fold that of activity with GTP alone. (-)Propranolol (1 μM) abolished the stimulation by (-)isoproterenol but did not inhibit the DA-stimulated adenylate cyclase, whereas a-flupenthixol (1 μM) inhibited DA stimulation but not that of (-)isoproterenol. The dopaminergic agonists epinine and BJ-dihydroxy-l, 2, 3, ...
Synthesis2
- Novel ligands for the human histamine H1 receptor: synthesis, pharmacology, and comparative molecular field analysis studies of 2-dimethylamino-5-(6)-phenyl-1,2,3,4-tetrahydronaphthalenes. (guidetopharmacology.org)
- Bidentate Lewis Acid Catalyzed Domino Diels-Alder Reaction of Phthalazine for the Synthesis of Bridged Oligocyclic Tetrahydronaphthalenes. (unibas.ch)